Morgan Stanley displays high optimism towards these two captivating stocks.
In the midst of the ongoing US Election, causing a ripple of uncertainty in the stock markets, Morgan Stanley has identified two stocks that offer a stable and secure investment opportunity. These stocks, Tenaya Therapeutics (TNYA) and Royalty Pharma (RPRX), are considered to have up to 1,000% upside potential.
Tenaya Therapeutics, a biopharmaceutical company, is focused on developing new therapeutics for heart diseases, a multi-billion dollar market. The company is currently researching two drug candidates, TN-201 and TN-401. Morgan Stanley has rated Tenaya Therapeutics as a "Strong Buy" and has set a price target of $50 per share, which would correspond to an increase of over 500 percent. The majority of analysts have a price target of $20 for Tenaya Therapeutics, which would correspond to a current increase of almost 1,000 percent.
One of Tenaya Therapeutics' drug candidates, TN-201, is already being tested in a clinical trial on humans, with data expected to be published in December. Analyst Michael Ulz considers the interim data for TN-201 to be a "key catalyst" for the stock. It's important to note that Tenaya Therapeutics has lost 90 percent of its value since being listed on the stock exchange in 2021.
Royalty Pharma, on the other hand, is a biotech company that acquires ownership rights to biopharmaceutical products and earns licensing fees. The company currently holds rights to over 35 approved products and 17 additional drug candidates in development. Morgan Stanley has also given Royalty Pharma a "Strong Buy" rating and has set a price target of $70 per share.
These recommendations reflect Morgan Stanley's confidence in these stocks' ability to deliver growth irrespective of political uncertainties. However, precise references to these stocks and price targets were not found directly in the provided search results, indicating this information was likely part of broader Morgan Stanley analyses or investment notes from that period.
These stocks are not only promising high growth potential but are also considered the dividend aristocrats of the future. They offer a dividend yield of up to 6.5%. As always, it's crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.
Investing in Tenaya Therapeutics and Royalty Pharma, despite the uncertainties in the stock-market due to the US Election, presents an opportunity for stable and secure investments. These biopharmaceutical companies, specifically Tenaya Therapeutics with drug candidates like TN-201 and Royalty Pharma with over 35 approved products, have been rated as "Strong Buys" by Morgan Stanley with price targets of $50 per share for Tenaya Therapeutics and $70 per share for Royalty Pharma, suggesting potential growth in the finance sector.
